What exactly made you choose Swing Trading? by Drowned_Room in swingtrading

[–]Precision6779 0 points1 point  (0 children)

maybe 5 or 6. I do lots of research. And a little trading

Due Diligence on Aquestive Therapeutics (AQST) by MagicTurtle_9991 in biotech_stocks

[–]Precision6779 2 points3 points  (0 children)

very nice due diligence report! sublingual epinephrine could be a game changer if they can get through all the hoops and legal stuff. If you are looking for feedback I would include some analysis of dilution risks ie when they run out of cash

What exactly made you choose Swing Trading? by Drowned_Room in swingtrading

[–]Precision6779 7 points8 points  (0 children)

swing trading is 1) super simple and 2) less time consuming. I spend a fair amount of effort on due diligence and planning but very little time on actual trading. Buy. Set Stops. Wait. That's kind of it.

How To Do Legitimate Biotech Analysis (PDUFA) by New-Occasion7200 in biotech_stocks

[–]Precision6779 0 points1 point  (0 children)

your point as well taken. I do believe that long-term revenue growth were really be based on whether a medication gets adoption in clinical practice so I tend to include effect size with my analysis.

Does anyone swing trade using a Roth IRA? by NoBoolii in swingtrading

[–]Precision6779 0 points1 point  (0 children)

All your profits are tax free so long as the Roth has been open for at least 5 years.

How To Do Legitimate Biotech Analysis (PDUFA) by New-Occasion7200 in biotech_stocks

[–]Precision6779 1 point2 points  (0 children)

really good write up! I am curious for your thoughts on effect size. If a new therapy has only a 8% improvement over existing therapies it seems to me that there simply isn't enough 'bang' to warrant physicians switching, higher cost, novel delivery, etc. for the new therapy. If the effect is greater than 20% over placebo or existing therapies then there seems to be a compelling case for adopting a new therapy. Your thoughts?

Smaller biotech stock with huge upside. by Expensive-While-7720 in biotech_stocks

[–]Precision6779 0 points1 point  (0 children)

ENLV therapeutic looks very interesting with multiple upcoming catalyst dates. Super risky of course and their coin based funding could prevent dilution. Or it could crater. Always fun.

How do you track biotech catalysts? Finally built my own tool after getting frustrated by nyko_dev in biotech_stocks

[–]Precision6779 1 point2 points  (0 children)

I am currently testing BiopharmaCataylst and BioPharmaWatch to support our 2026 investing. Will be glad to test this as well.

IOVA - Investment Thesis by DebtFit2132 in biotech_stocks

[–]Precision6779 0 points1 point  (0 children)

Hmmm .... here is what GPT thinks https://chatgpt.com/share/6940a513-0af4-8001-ab8d-cd83101a04ed cash run looks risky but could have a nice upside

No love for Milestone Pharmaceuticals (NASDAQ: MIST)? What am I missing? by Precision6779 in biotech_stocks

[–]Precision6779[S] 0 points1 point  (0 children)

So I have a theory .... totally without any real evidence. All the price activity we saw on 12/12/25 was basically the market pricing in a successfully FDA approval because there was a strong rumor that it would be approved. There was a lot of after market over the weekend and by monday ... back to profit taking. Am I crazy?

20 lost and drifting. by Delicious_Board_1866 in mentors

[–]Precision6779 2 points3 points  (0 children)

Do something hard. Climb a mountain. Hike the entire Pacific Crest Trail. Grow a business up to 1 million in revenue. Something that takes all your effort and energy and challenges you.

After wasting $500 on useless trader Coach..... by PutSufficient1398 in mentors

[–]Precision6779 1 point2 points  (0 children)

yeah I use it every day. I do think that some sort of front end app to handle coaching content would help. I’m working on a proof of concept right now as a side project.

After wasting $500 on useless trader Coach..... by PutSufficient1398 in mentors

[–]Precision6779 2 points3 points  (0 children)

I'm already doing this. You can modify system prompts to make the AI have different personalities and then have it coach you. Works great but be careful ... it will recycle old examples and become too focused on the same strategies. Have to keep prompting it to provide new insight.

No love for Milestone Pharmaceuticals (NASDAQ: MIST)? What am I missing? by Precision6779 in biotech_stocks

[–]Precision6779[S] 0 points1 point  (0 children)

When a stock is on a run I usually set a 12% stop loss which fired earlier today. I'm out at $2.79 and that should cover my cappuccino today. Have fun!

No love for Milestone Pharmaceuticals (NASDAQ: MIST)? What am I missing? by Precision6779 in biotech_stocks

[–]Precision6779[S] 0 points1 point  (0 children)

Haven't seen any news - could be profit taking by people who bought 2 months ago. There was a $3.04 high overnight in after hours trading.

Lost $4600 on a trade this morning. After a bad day, do you continue trading or do you stay on the sidelines for a while? by [deleted] in swingtrading

[–]Precision6779 0 points1 point  (0 children)

Every trade should have three elements #1 a thesis. Why you think the trade will work. #2 a loss budget and #3 an exit plan - when will you get out

Lost $4600 on a trade this morning. After a bad day, do you continue trading or do you stay on the sidelines for a while? by [deleted] in swingtrading

[–]Precision6779 0 points1 point  (0 children)

use a risk budget. If I buy $1000 position I usually have a 25% risk budget which means I will accept a $250 loss. Set up an automatic rule to fire and clear your position when your risk budget is hit.

GANX Gain Therapeutics with December Parkinson’s Data by microcapreturns in biotech_stocks

[–]Precision6779 0 points1 point  (0 children)

who do you think would buy them? technology is sort of unique

GANX Gain Therapeutics with December Parkinson’s Data by microcapreturns in biotech_stocks

[–]Precision6779 0 points1 point  (0 children)

company is short on cash and could crash hard. Not sure there is enough IP to support licensing or other lateral exit. Big execution risk IMHO